SCD and metabolic dysfunction-associated steatotic liver disease: The end-result of SCD1 inhibition may, therefore, be an aggravation of NASH due to intracellular accumulation of cytotoxic saturated fatty acids [51, 62], placing the partitioning of saturated fatty acids to mono-unsaturated fatty acids as a protective factor in delaying NAFLD progression.